Trialbee Partners With LiveRamp
Trialbee has announced a partnership with LiveRamp, to expand the pool of potential patients and then match and engage patients for clinical trials in a privacy-centric way. Trialbee will leverage LiveRamp’s identity infrastructure and integration network to identify and reach potential clinical trial patients and remain engaged with those patients throughout their clinical trial journey.
Over 80% of regulated phase II-III clinical trials fail to meet planned enrollment targets and are delayed six or more months, jeopardizing data quality and development timelines. Inefficient and untargeted recruitment efforts for late-stage trials cause rise in direct operational development costs and lost revenues due to delayed time to market.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
